Endothelial CYP2J2 and CYP2C8 Overexpression and Soluble Epoxide Hydrolase Deletion Attenuate Acute Inflammatory Responses in Mice

被引：0
|
作者：
Deng, Yangmei [1 ]
Theken, Katherine N. [1 ]
Edin, Matthew L. [2 ]
Kannon, M. Alison [1 ]
Schuck, Robert N. [1 ]
DeGraff, Laura M. [2 ]
Bradbury, J. Alyce [2 ]
Graves, Joan [2 ]
Zeldin, Darryl C. [2 ]
Lee, Craig R. [1 ]
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] Natl Inst Environm Hlth Sci, Rsch Triangle Pk, NC USA
来源：
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY | 2009年 / 29卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：E63 / E63
页数：1
相关论文
共 50 条
  • [41] Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide
    Kajosaari, LI
    Jaakkola, T
    Neuvonen, PJ
    Backman, JT
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2006, 62 (03) : 217 - 223
  • [42] Gene structure of CYP2C8 and extrahepatic distribution of the human CYP2Cs
    Klose, TS
    Blaisdell, JA
    Goldstein, JA
    JOURNAL OF BIOCHEMICAL AND MOLECULAR TOXICOLOGY, 1999, 13 (06) : 289 - 295
  • [43] Tucatinib inhibits CYP3A, CYP2C8 and P-gp-mediated elimination and is impacted by CYP2C8 inhibition in healthy volunteers
    Topletz-Erickson, Ariel R.
    Lee, Anthony
    Sun, Hao
    Mayor, JoAl
    Walker, Luke
    Endres, Christopher J.
    CANCER RESEARCH, 2020, 80 (16)
  • [44] Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide
    Lauri I. Kajosaari
    Tiina Jaakkola
    Pertti J. Neuvonen
    Janne T. Backman
    European Journal of Clinical Pharmacology, 2006, 62 : 217 - 223
  • [45] Interplay of UDP-Glucuronosyltransferase and CYP2C8 for CYP2C8 Mediated Drug Oxidation and Its Impact on Drug-Drug Interaction Produced by Standardized CYP2C8 Inhibitors, Clopidogrel and Gemfibrozil
    Iga, Katsumi
    Kiriyama, Akiko
    CLINICAL PHARMACOKINETICS, 2024, 63 (01) : 43 - 56
  • [46] Response and neurologic toxicity to taxano regarding to CYP2C8*3 and CYP2C8*2 polymorphisms in Peruvian breast cancer cases.
    Alcarraz, Cindy
    Altamirano, Carlos Castaneda
    Gomez, Henry
    Zavaleta, Amparo
    Flores, Carol
    Garcia, Miluska Castillo
    Cerna, Ketty Dolores
    Saba, Julio E. Abugattas
    Vidaurre, Tatiana
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [47] CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast
    Karonen, Tiina
    Neuvonen, Pertti J.
    Backman, Janne T.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2012, 73 (02) : 257 - 267
  • [48] Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity
    Zhang, Yunfang
    El-Sikhry, Haitham
    Chaudhary, Ketul R.
    Batchu, Sri Nagarjun
    Shayeganpour, Anooshirvan
    Jukar, Taibeh Orujy
    Bradbury, J. Alyce
    Graves, Joan P.
    DeGraff, Laura M.
    Myers, Page
    Rouse, Douglas C.
    Foley, Julie
    Nyska, Abraham
    Zeldin, Darryl C.
    Seubert, John M.
    AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY, 2009, 297 (01): : H37 - H46
  • [49] EFFECT OF AGING ON POSTISCHEMIC FUNCTIONAL RECOVERY OF CYP2J2 TRANSGENIC MICE
    Chaudhary, K. R.
    Batchu, S.
    Seubert, J. M.
    CANADIAN JOURNAL OF CARDIOLOGY, 2010, 26 : 32D - 32D
  • [50] Genetic polymorphisms of CYP2C8 in Japanese population
    Nakajima, M
    Fujiki, Y
    Noda, K
    Ohtsuka, H
    Ohkuni, H
    Kyo, S
    Inoue, M
    Kuroiwa, Y
    Yokoi, T
    DRUG METABOLISM AND DISPOSITION, 2003, 31 (06) : 687 - 690
12345